18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer

Fahad Marafi 1, Arun Sasikumar 2, Mahamoud Alfeeli 1, Sanjay Thuruthel 3

Affiliations

01 June 2020

-

doi: 10.1097/RLU.0000000000003013

Abstract

A 72-year-old man, who is known with a case of metastatic carcinoma of the breast, was referred for F-PMSA 1007 PET/CT with clinical suspicion of synchronous prostate cancer. F-PSMA 1007 PET/CT scan detected no abnormal tracer concentrating lesion in the prostate gland; however, abnormal tracer concentration was noted in soft tissue lesions in left breast, metastatic lymph nodes, and skeletal lesions. Compared with F-FDG PET/CT, more bone lesions were detected on F-PSMA 1007 imaging. The findings of our case open the possibility of imaging metastatic breast cancer with F-PSMA 1007 in men.

Similar articles

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.PMID: 30843003

18F-PSMA-1007 Uptake in Pulmonary Lymphangitic Carcinomatosis Metastasis From Prostate Cancer.

Liu BL, Hong JJ, Tang K, Lin J, Zheng XW.Clin Nucl Med. 2021 Jul 1;46(7):e355-e357. doi: 10.1097/RLU.0000000000003582.PMID: 33782286

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.PMID: 29419475

18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer.

Marafi F, Sasikumar A, Alfeeli M, Fathallah W.Clin Nucl Med. 2020 Feb;45(2):e77-e79. doi: 10.1097/RLU.0000000000002821.PMID: 31693624

Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT.

Tang K, Wang Z, Lin J, Zheng X.Clin Nucl Med. 2020 Mar;45(3):223-224. doi: 10.1097/RLU.0000000000002873.PMID: 31876816

Cited by

F-18 PSMA Uptake in Male Breast Cancer during Restaging Evaluation of Carcinoma Prostate.

Zade A, Shetty S, Ambekar A, Karpe M.Indian J Nucl Med. 2022 Jul-Sep;37(3):277-278. doi: 10.4103/ijnm.ijnm_127_21. Epub 2022 Nov 2.PMID: 36686311 Free PMC article.

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J.Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12.PMID: 34120192 Free PMC article. Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Sasikumar A, Joy A, Pillai AMR, et al. Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma. Nucl Med Commun. 2018;39:1013–1021.
  2.  
    1. Zhang J, Shao S, Wu P, et al. Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. Eur J Nucl Med Mol Imaging. 2019;46:908–920.
  3.  
    1. Pianou NK, Stavrou PZ, Vlontzou E, et al. More advantages in detecting bone and soft tissue metastases from prostate cancer using (18)F-PSMA PET/CT. Hell J Nucl Med. 2019;22:6–9.
  4.  
    1. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2018;45:340–347.
  5.  
    1. Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678–688.
  6.  
    1. Giesel FL, Will L, Kesch C, et al. Biochemical recurrence of prostate Cancer: initial results with [(18)F]PSMA-1007 PET/CT. J Nucl Med. 2018;59:632–635.
  7.  
    1. Kesch C, Vinsensia M, Radtke JP, et al. Intraindividual comparison of 18F-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study. J Nucl Med. 2017;58:1805–1810.
  8.  
    1. Seifert R, Schafigh D, Bogemann M, et al. Detection of local relapse of prostate cancer with 18F-PSMA-1007. Clin Nucl Med. 2019;44:e394–e395.
  9.  
    1. Kumar R, Mittal BR, Bhattacharya A, et al. Synchronous detection of male breast cancer and prostatic cancer in a patient with suspected prostatic carcinoma on 68Ga-PSMA PET/CT imaging. Clin Nucl Med. 2018;43:431–432.
  10.  
    1. Polverari G, Ceci F, Calderoni L, et al. Male breast cancer detected by 68Ga-PSMA-11 PET/CT in a patient with prostate cancer with pelvic lymph node metastasis. Clin Genitourin Cancer. 2019;17:154–156.
  11.  
    1. Sathekge M, Lengana T, Modiselle M, et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–694.
  12.  
    1. Sasikumar A, Joy A, Nair BP, et al. False positive uptake in bilateral gynecomastia on 68Ga-PSMA PET/CT scan. Clin Nucl Med. 2017;42:e412–e414.
  13.  
    1. Malik D, Basher RK, Mittal BR, et al. 68Ga-PSMA expression in pseudoangiomatous stromal hyperplasia of the breast. Clin Nucl Med. 2017;42:58–60.

Page Navigation